Rucaparib companion diagnostic - Clovis Oncology/Foundation Medicine

Drug Profile

Rucaparib companion diagnostic - Clovis Oncology/Foundation Medicine

Alternative Names: CDxBRCA; FoundationFocus CDxBRCA; Rubraca companion diagnostic

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Clovis Oncology; Foundation Medicine
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Ovarian cancer
  • Phase III Fallopian tube cancer; Peritoneal cancer

Most Recent Events

  • 19 Dec 2016 Registered for Ovarian cancer (Diagnosis) in USA - First global approval
  • 23 Aug 2016 Preregistration for Ovarian cancer (Diagnosis) in USA (unspecified route)
  • 05 May 2016 Clovis Oncology announces intention to submit PMA application to US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top